Table 2.
Targets | HCC | LCI | HCI | p value |
---|---|---|---|---|
ANGIOGENESIS PROTEINS | ||||
VEGF | 1 ± 0.366 | 1.96 ± 0.819 | 1.30 ± 0.245 | 0.02* |
VEGF R1 | 1 ± 0..208 | 1.71 ± 0.380 | 1.26 ± 0.289 | 0.0003*‡ |
VEGF R2 | 1 ± 0.249 | 2.42 ± 0.839 | 1.19 ± 0.244 | 0.0003*‡ |
VE Cadherin | 1 ± 0.258 | 1.23 ± 0.172 | 1.77 ± 0.576 | 0.58 |
iNOS | 1 ± 0.379 | 1.01 ± 0.344 | 1.71 ± 1.390 | 0.21 |
ERK | 1 ± 0.322 | 1.41 ± 0.508 | 1.33 ± 0.794 | 0.32 |
pERK | 1 ± 0.469 | 1.23 ± 0.594 | 1.25 ± 0.538 | 0.54 |
Endostatin | 1 ± 0.401 | 1.02 ± 0.278 | 0.97 ± 0.484 | 0.99 |
Angiopoietin 1 | 1 ± 0.710 | 1.16 ± 0.599 | 0.90 ± 0.479 | 0.67 |
STRUCTURAL PROTEINS | ||||
RhoA | 1 ± 0.198 | 1.08 ± 0.305 | 1.03 ± 0.226 | 0.21 |
Tau | 1 ± 0.342 | 1.08 ± 0.373 | 1.06 ± 0.372 | 0.91 |
Talin | 1 ± 0.115 | 1.71 ± 0.179 | 1.79 ± 0.496 | 0.0002*† |
Paxillin | 1 ± 0.386 | 0.91 ± 0.309 | 1.47 ± 0.296 | 0.11 |
Vinculin | 1 ± 1.179 | 0.65 ± 0.424 | 0.71 ± 0.342 | 0.60 |
Protein expression listed as fold change ± SD compared to HCC. One way analysis of variance performed to determine p value. Bonferroni multiple comparison tests were performed:
indicates significant difference between HCC and LCI group.
indicates significant difference between HCC and HCI.
indicates significant difference between LCI and HCI group. HCC: High Cholesterol Control; LCI: Low Dose Calpain Inhibitor; HCI: High Dose Calpain Inhibitor